Page 1 | Search Results | Blood | American Society of Hematology

1-14 of 14

Sort by

Sort Order Select

Journal Articles

CAR-T with ICOS costimulation lacks therapeutic efficacy in patient due to strong trogocytosis and failure of expansion

Yongxia Wu, Allison Pugel, Katie Palen, Peiman Hematti, Tyce Kearl, Rimas Orentas, Timothy Fenske, Mehdi Hamadani, Walter Longo, Bryon Johnson, Nirav Shah, Xue-Zhong Yu

Blood (2025) 146 (Supplement 1): 2346.

https://doi.org/10.1182/blood-2025-2346

Published: 2025

Journal Articles

Optimizing the manufacturing and delivery of LV20.19 CAR T cells for relapsed, refractory DLBCL and FL

Nirav Shah, Maria Poimenidou, Adam Kidwell, Aniko Szabo, Tyce Kearl, Bryon Johnson, Anthony Stillwell, Sumana Devata, Kaitlin Annunzio, Rimas Orentas, Walter Longo, Timothy Fenske, Peiman Hematti, Michael Dwinell, Mehdi Hamadani

Blood (2025) 146 (Supplement 1): 2401.

https://doi.org/10.1182/blood-2025-2401

Published: 2025

Journal Articles

Cladribine based salvage chemotherapy in AML patients with persistent or recurrent disease after venetoclax/HMA

Sameem Abedin, Guru Subramanian Guru Murthy, Karen-Sue Carlson, Lyndsey Runaas, Walter Longo, Laura Michaelis, Ehab Atallah

Blood (2025) 146 (Supplement 1): 5238.

https://doi.org/10.1182/blood-2025-5238

Published: 2025

Journal Articles

Split dose R-CHOP mitigates toxicity while preserving dose intensity and response in frail elderly patients with diffuse large B cell lymphoma (DLBCL) - a Wisconsin oncology network (WON) study

Christopher Fletcher, Aniko Szabo, Sumana Devata, Vaishalee Kenkre, Priyanka Pophali, Luke Zurbriggen, Julie Chang, Katina Deshong, Mitch Howard, Mariah Endres, Joel Pollen, Esta Konkol, Walter Longo, Mehdi Hamadani, Timothy Fenske, Saurabh Rajguru, Nirav Shah

Blood (2025) 146 (Supplement 1): 1964.

https://doi.org/10.1182/blood-2025-1964

Published: 2025

Journal Articles

Split-Dose R-CHOP for Older Patients with Treatment Naïve DLBCL

Adam Kidwell, Fateeha Furqan, Emilie Aschenbrenner, Walter Longo, Sumana Devata, Mehdi Hamadani, Timothy S. Fenske, Nirav N. Shah

Blood (2024) 144 (Supplement 1): 2374.

https://doi.org/10.1182/blood-2024-203974

Published: 2024

Journal Articles

Ruxolitinib Resistance or Intolerance in Steroid-Refractory Chronic Graft-Versus-Host Disease - a Real-World Single Center Analysis

Gulrayz Ahmed, Amer Al Homssi, Ramsha Ahmed, Walter Longo, Nirav N. Shah, Lyndsey Runaas, Marcelo C. Pasquini, Timothy S. Fenske, Lisa E Rein, Aniko Szabo, Mehdi Hamadani, Sameem Abedin

Blood (2024) 144 (Supplement 1): 7346.

https://doi.org/10.1182/blood-2024-209225

Published: 2024

Journal Articles

Cytogenetic Abnormalities Following CAR T Cell Therapy for B-Cell Malignancies

Na Hyun Kim, Fatima Khamissi, Kathleen Bone, Nathan Kopp, Walter Longo, Bryon D. Johnson, Tyce Kearl, Peiman Hematti, Mehdi Hamadani, Timothy S. Fenske, Nirav N. Shah

Blood (2024) 144 (Supplement 1): 3459.

https://doi.org/10.1182/blood-2024-205752

Published: 2024

Journal Articles

Phase 1 Study of Trispecific Anti-CD20, Anti-CD19, Anti-CD22 (CAR20.19.22) T Cells for Relapsed, Refractory B-Cell Malignancies

Nirav N. Shah, Aniko Szabo, Tyce Kearl, Dina Schneider, Walter Longo, Bryon D. Johnson, Peiman Hematti, Mehdi Hamadani, Timothy S. Fenske

Blood (2024) 144 (Supplement 1): 3448.

https://doi.org/10.1182/blood-2024-200899

Published: 2024

Journal Articles

Early Safety and Feasibility Results from a Phase II Trial of De-Escalated Ptcy and Ruxolitinib for Gvhd Prophylaxis in Older Patients Undergoing Reduced Intensity Conditioning Allogeneic HCT

Sameem Abedin, Fateeha Furqan, Lyndsey Runaas, Walter Longo, Nirav N. Shah, Timothy S. Fenske, Marcelo C. Pasquini, William R Drobyski, Xue-Zhong Yu, Mehdi Hamadani

Blood (2024) 144 (Supplement 1): 1039.

https://doi.org/10.1182/blood-2024-200832

Published: 2024

Journal Articles

Adaptive Manufacturing of LV20.19 CAR T-Cells for Relapsed, Refractory Mantle Cell Lymphoma

Nirav N. Shah, Fateeha Furqan, Aniko Szabo, Tyce Kearl, Anthony Zamora, Jessica Neumann, Parameswaran N. Hari, Dina Schneider, Walter Longo, Peiman Hematti, Bryon D. Johnson, Mehdi Hamadani, Timothy S. Fenske

Blood (2023) 142 (Supplement 1): 1024.

https://doi.org/10.1182/blood-2023-173954

Published: 2023

Journal Articles

Real-World Experience with RTOG 0227 Induction for First Line Therapy of Primary CNS Lymphoma (PCNSL)

Ramsha Ahmed, Precious Anyanwu, Nirav N. Shah, Mehdi Hamadani, Walter Longo, Sumana Devata, Julie Pruett, Jennifer Connelly, Joseph Bovi, Malika Siker, Christopher Schultz, Timothy S. Fenske

Blood (2023) 142 (Supplement 1): 3122.

https://doi.org/10.1182/blood-2023-190961

Published: 2023

Journal Articles

The Addition of Bevacizumab (B) to Lenalidomide and Low Dose Dexamethasone Does Not Significantly Increase Response in Relapsed or Refractory Multiple Myeloma (NCI#7317).

Natalie Scott Callander, MD, Stephanie Markovina, BA, Mark B. Juckett, MD, Elizabeth Wagner, MA, Jill Kolesar, Walter Longo, Eliot C. Williams, MD, PhD, Kyungmann Kim, Jae Werndli, BSc, MSc, Shigeki Miyamoto, PhD

Blood (2009) 114 (22): 3885.

https://doi.org/10.1182/blood.V114.22.3885.3885

Published: 2009

Journal Articles

VcR-CVAD Produces a High Complete Response Rate in Untreated Mantle Cell Lymphoma: A Phase II Study from the Wisconsin Oncology Network

Brad Kahl, Julie Chang, Jens Eickhoff, Leslie Gilbert, Eric Rogers, Jae Werndli, Michael Huie, Thomas McFarland, Michael Volk, Jules H. Blank, Natalie Callander, Walter Longo, Christopher Peterson

Blood (2008) 112 (11): 265.

https://doi.org/10.1182/blood.V112.11.265.265

Published: 2008

Journal Articles

Phase II Trial of Bevacizumab Combined with Low Dose Dexamethasone and Lenalidomide (BEV/REV/DEX) for Relapsed or Refractory Myeloma (MM).

Martha Raschko, MD, Stephanie Markovina, Shigeki Miyamoto, PhD, Walter Longo, MD, Eliot Williams, MD, Thomas McFarland, MD, Jae Werndli, Elisabeth Wagner, Mark Juckett, MD, Natalie Callander, MD

Blood (2007) 110 (11): 1173.

https://doi.org/10.1182/blood.V110.11.1173.1173

Published: 2007

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

CAR-T with ICOS costimulation lacks therapeutic efficacy in patient due to strong trogocytosis and failure of expansion

Optimizing the manufacturing and delivery of LV20.19 CAR T cells for relapsed, refractory DLBCL and FL

Cladribine based salvage chemotherapy in AML patients with persistent or recurrent disease after venetoclax/HMA

Split dose R-CHOP mitigates toxicity while preserving dose intensity and response in frail elderly patients with diffuse large B cell lymphoma (DLBCL) - a Wisconsin oncology network (WON) study

Split-Dose R-CHOP for Older Patients with Treatment Naïve DLBCL

Ruxolitinib Resistance or Intolerance in Steroid-Refractory Chronic Graft-Versus-Host Disease - a Real-World Single Center Analysis

Cytogenetic Abnormalities Following CAR T Cell Therapy for B-Cell Malignancies

Phase 1 Study of Trispecific Anti-CD20, Anti-CD19, Anti-CD22 (CAR20.19.22) T Cells for Relapsed, Refractory B-Cell Malignancies

Early Safety and Feasibility Results from a Phase II Trial of De-Escalated Ptcy and Ruxolitinib for Gvhd Prophylaxis in Older Patients Undergoing Reduced Intensity Conditioning Allogeneic HCT

Adaptive Manufacturing of LV20.19 CAR T-Cells for Relapsed, Refractory Mantle Cell Lymphoma

Real-World Experience with RTOG 0227 Induction for First Line Therapy of Primary CNS Lymphoma (PCNSL)

The Addition of Bevacizumab (B) to Lenalidomide and Low Dose Dexamethasone Does Not Significantly Increase Response in Relapsed or Refractory Multiple Myeloma (NCI#7317).

VcR-CVAD Produces a High Complete Response Rate in Untreated Mantle Cell Lymphoma: A Phase II Study from the Wisconsin Oncology Network

Phase II Trial of Bevacizumab Combined with Low Dose Dexamethasone and Lenalidomide (BEV/REV/DEX) for Relapsed or Refractory Myeloma (MM).

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only